November 18, 2024
PanFlu Wins BioTech Breakthrough Award For 2024 “Monoclonal Antibody Solution Of The Year”
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries
PanFlu is the recipient of the “Monoclonal Antibody Solution of the Year” award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
“Current seasonal flu vaccines don’t always protect optimally, especially for the elderly and other vulnerable groups. We envision a world where people of all ages and risk profiles have the option to protect themselves at any moment, at any place, against any form of influenza,” said Koenraad Wiedhaup, a founder and CEO of Leyden Labs. “Thank you to BioTech Breakthrough for recognizing PanFlu’s potential to accomplish this ambitious goal.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
“PanFlu could fill the gap between vaccines and antiviral treatments by introducing a novel approach to infection prevention. Although largely normalized, flu continues to pose a threat to public health worldwide with millions dying from influenza-related respiratory causes annually. Vaccination is a critical tool and yet due to strain/vaccine mismatch and those with weakened immune systems, it is imperfect,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “Mucosal protection with PanFlu has the potential to provide people further control to protect themselves from seasonal flu, and could also play a key role in preventing future flu pandemics. We are pleased to recognize Leyden Labs with ‘Monoclonal Antibody Solution of the Year!’”
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
© Leyden Labs, 2023 | Privacy Statement | Design by Ape to Zebra
